Evidence map›Paper›PMID 41524959›Full record

ArticlePituitary2026

Long-term cabergoline use does not predict degree of prolactinoma fibrosis nor significantly impact surgical outcomes.

Adam N Mamelak, Rachel Fox, Yaakov Rosenberg, Daniel Gomez, Yujie Cui, Anat Ben-Shlomo, Artak Labadzhyan, Ning-Ai Liu, Vivien Bonert, Odelia Cooper

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pituitary, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors.

Adam N MamelakDepartment of Neurosurgery, Cedars-Sinai Medical Center, 127 S. San Vicente Blvd., Ste. A6313, Los Angeles, CA, 90035, USA. mamelaka@cshs.org.ORCID http://orcid.org/0000-0002-4245-6431
Rachel Fox *Department of Neurosurgery, Cedars-Sinai Medical Center, 127 S. San Vicente Blvd., Ste. A6313, Los Angeles, CA, 90035, USA.
Yaakov Rosenberg *Department of Neurosurgery, Cedars-Sinai Medical Center, 127 S. San Vicente Blvd., Ste. A6313, Los Angeles, CA, 90035, USA.
Daniel GomezPituitary Center, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Yujie CuiBiostatistics Shared Resource, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Anat Ben-ShlomoPituitary Center, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Artak LabadzhyanPituitary Center, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Ning-Ai LiuPituitary Center, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Vivien BonertPituitary Center, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Odelia CooperPituitary Center, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeProlactinomas are often treated initially with dopamine agonists (DA). For patients subsequently treated with surgery, the effect of cabergoline (CAB) on tumor fibrosis and its potential impact on surgical outcomes is largely unexplored.

methodsRecords of patients with prolactinoma treated by a single surgeon between 2006 and 2024 were examined. Analyses considered relationships among duration and cumulative dose of presurgical DA (DA + vs. DA-), extent of fibrosis measured quantitatively by collagen volume fraction (CVF) and qualitatively by surgeon assessment, and remission status at last follow-up.

resultsOf 59 patients, 22 were DA- and 37 were DA+, including 29 treated only with CAB and 8 treated with CAB and bromocriptine. There were 44 macroadenomas, 13 microadenomas, and 2 giant adenomas; 28 had cavernous sinus invasion (Knosp grade 3-4) 52.5% were in remission at last follow-up. Median cumulative CAB dose was 79.3 mg (range, 5.4-6711), used for a median duration of 570 days (range, 16-7830). Neither CAB dose nor duration correlated with CVF (r

conclusionDuration and cumulative dose of presurgical CAB use do not correlate with quantitative measures of tumor fibrosis and do not reliably predict the degree of fibrosis at surgery or the likelihood of surgical remission.

Indexed as

CabergolinePituitary NeoplasmsProlactinomaAdultAgedDopamine AgonistsFemaleFibrosisHumansMaleMiddle AgedRetrospective StudiesTreatment OutcomeCabergolineDopamine AgonistsCabergolineCavernous sinus invasionCollagen volume fractionDopamine agonistProlactinomaRemission

Identifiers

PMID41524959
PMCPMC12795900

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.